ipamorelin e tesamorelin + Blend — GHRH Research Tesamorelin + Ipamorelin Peptides |

The polyethylene glycol chains improve the physiological stability and water solubility

8 , eabk1792 (2022)

Inject both peptides simultaneously for maximum pulse

In certain embodiments, pharmaceutical compositions in accordance with the present disclosure may be administered at dosage levels sufficient to deliver from about 0.0001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, from about 0.1 mg/kg to about 40 mg/kg, from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, or from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic, diagnostic or prophylactic effect

Peptide Therapy CJC ipamorelin vs sermorelin compared by mechanism, evidence, dosing, and failure modes

This peptide is designed to stimulate the release of growth hormone from the pituitary gland in a pulsatile manner, leading to increased levels of growth hormone in the body